This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Diabetes, Metabolic Syndrome And Cardiovascular Disease

TABLE OF CONTENTS

1. Overview 8

1.1 Statement of Report 8

1.2 About this Report 8

1.3 Scope of the Report 9

1.4 Methodology 9

1.5 Executive Summary 10

2. Introduction 152.1 Demographics of Diabetes 162.1.1 Worldwide Diabetes 162.1.2 U.S. Diabetes 182.2 Economics of Diabetes 21

3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes 26

3.1 Pre-Diabetes Syndrome 27

3.2 Metabolic Syndrome 27

3.3 Diabetes and Inflammation 32

3.4 Diagnosis of Diabetes Mellitus 33

3.5 Progression of Diabetes 33

3.6 Risk Factors and Diabetes 33

3.6.1 Obesity 34

3.6.2 Stress-Induced Hyperglycemia 37

3.7 Complications and Co-Morbidities in Type 2 Diabetes 37

3.7.1 Preventing Complications and Co-Morbidities in Diabetes 40

3.8 Hypoglycemia Resulting from Treatment 41

3.9 Cardiovascular Disease (CVD) 41

3.9.1 CVD Facts 41

3.9.2 Cardiac Care Therapeutics 48

3.9.2.1 Anti-Hypertensive Drugs 49

3.9.2.2 Cholesterol Management Drugs 50

3.9.2.3 Anticoagulants 53

3.9.3 CVD Diagnostics 53

4. Pharmaceutical Industry and the Anti-Diabetes Market 564.1 The Worldwide Pharmaceutical Industry 564.1.1 Pharmaceutical R&D Spending by Type, Growth Rate and Expenditure 564.1.2 Global Pharmaceutical Market 584.2 Total Diabetes Drug Market Size and Growth 624.2.1 Sales of Anti-Diabetic Drugs Continue to Rise 654.3 Diabetic Medications Overview 664.3.1 Recent Trends in Diabetic Drug Usage 674.3.2 Market Influence Factors 71

5. Non-Insulin Anti-Diabetes Products 73

5.1 Anti-Diabetic Drug Therapy Overview 73

5.1.1 Sulfonylureas 77

5.1.2 Meglitinides 78

5.1.3 Biguanides 79

5.1.4 Thiazolidinediones (TZDs) 80

5.1.5 a-Glucosidase Inhibitors 82

5.1.6 Incretin Mimetics/Glucagon-like Peptide (GLP-1) Analogs and Agonists 83

5.1.6.1 Byetta (Exenatide) 84

5.1.6.2 Victoza (Liraglutide) 85

5.1.6.3 Bydureon (Exenatide LAR) 85

5.1.7 Amylin Analog 85

5.1.8 DPP-IV Inhibitors 86

5.1.8.1 Januvia (Sitagliptin) 86

5.1.8.2 Onglyza (Saxagliptin) 86

5.1.8.3 Tradjenta (Linagliptin) 86

5.1.8.4 Galvus (Vildagliptin) 87

5.1.9 Combination Therapy 87

5.1.9.1 Youth with Recent-Onset Type 2 Diabetes should be Started on Combination

Therapies 88

2 of 9

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,265.99 +109.14 0.64%
S&P 500 2,011.36 +9.79 0.49%
NASDAQ 4,593.4250 +31.2360 0.68%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs